FLGT

Over the past six months, Fulgent Genetics' stock experienced a 38.09% drop on February 27, 2026, after reporting 2025 full-year earnings, partly due to a major customer moving lab testing in-house. On March 17, 2026, the company completed the acquisition of Bako Diagnostics and StrataDx, expanding its pathology services. The stock decreased by 6.98% on May 1, 2026, following the announcement of Q1 2026 financial results, which showed a 3% year-over-year revenue decline and a net loss. Updated FID-007 data presented at ASCO 2026 led to a slight stock decrease on May 21 (-1.55%) and an increase on June 1 (+3.37%). On July 30, 2026, the stock fell 18.11% after Q2 2026 financial results revealed a wider-than-expected adjusted loss, missed revenue estimates, and reduced full-year guidance. In Q1 2026, Fulgent repurchased approximately 2.6 million shares for $40.1 million. A Form 4 filing on September 3, 2026, indicated the CFO's shareholdings after tax withholding. Overall, the stock price has lost 3.6% over the past 12 months.